Driehaus Cap Mngmt Llc accumulated 574,495 shares. BTIG Research assumed coverage on shares of Loxo Oncology in a research report on Friday, January 6th. Advisory Research Incorporated has invested 0.04% in Loxo Oncology, Inc. About 609,082 shares traded or 51.30% up from the average. (NASDAQ:LOXO) that has shown a discernible change in trend levels over the path of recent market activity. LOXO outperformed by 135.25% the S&P500.
In other Loxo Oncology news, VP Jennifer Burstein sold 1,700 shares of the firm's stock in a transaction on Monday, February 12th. The Folger Nolan Fleming Douglas Capital Management Inc holds 88,499 shares with $9.46 million value, down from 92,354 last quarter. The firm has a market cap of $3,693.90, a PE ratio of -25.13 and a beta of 2.32.
The stock increased 8.50% or $10.46 during the last trading session, reaching $133.45. About 4.19 million shares traded. Stifel Nicolaus maintained Loxo Oncology, Inc. It has outperformed by 56.74% the S&P500. (NASDAQ:LOXO). Lord Abbett And Ltd reported 551,808 shs. They expect $-0.44 earnings per share, up 54.17 % or $0.52 from last year's $-0.96 per share. (NASDAQ:GILD). Cibc holds 1.22 million shares or 0.63% of its portfolio. -36.23 % EPS growth is what Wall Street's forecasts after $-0.69 reported EPS last quarter. The Williams %R fluctuates between 0 and -100 measuring whether a security is overbought or oversold. Therefore 91% are positive. The company was maintained on Friday, October 6 by Morgan Stanley. The company was maintained on Thursday, June 8 by Needham. The firm has "Buy" rating given on Thursday, June 8 by Stifel Nicolaus. (NYSE:JPM) has "Hold" rating given on Thursday, January 11 by Credit Suisse. As per Wednesday, July 29, the company rating was maintained by Maxim Group. The rating was maintained by Deutsche Bank with "Hold" on Tuesday, July 19. The rating was maintained by Robert W. Baird on Friday, October 13 with "Neutral". (NASDAQ:LOXO) shares with value of $20.13M were sold by AISLING CAPITAL III LP. (NASDAQ:LOXO) or 250,000 shares. Cambridge Investment Research Advisors Inc. bought a new position in Loxo Oncology in the third quarter worth approximately $212,000. Bonita David P also sold $20.63M worth of Loxo Oncology, Inc. Strs Ohio reported 1,000 shares stake. Bilenker Joshua H. had sold 15,000 shs worth $1.97 million on Tuesday, March 13.
Big Money Sentiment decreased to 0.97 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3.
N/A of Loxo Oncology shares are owned by institutional investors. 23 funds acquired holdings and 47 increased holdings. 124.82 million shares or 329.48% more from 29.06 million shares in 2017Q3 were reported. Millennium Mgmt Limited Liability Corp invested 0% in Loxo Oncology, Inc. Citigroup restated a "buy" rating and set a $151.00 target price (up from $108.00) on shares of Loxo Oncology in a report on Monday, March 5th.
TIAA CREF Investment Management LLC cut its holdings in Loxo Oncology (NASDAQ:LOXO) by 4.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. (NASDAQ:LOXO) or 5,360 shares. The firm owned 205,082 shares of the biopharmaceutical company's stock after selling 12,144 shares during the period. Great West Life Assurance Can owns 2,958 shares. First Personal reported 0% stake. As per Wednesday, September 27, the company rating was maintained by Stifel Nicolaus. Perigon Wealth Mngmt Lc reported 100 shares or 0% of all its holdings. Pictet Asset Limited accumulated 220,764 shares. State Street Corporation stated it has 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Barclays Public Limited Co holds 0% of its portfolio in Loxo Oncology, Inc. QS Investors LLC acquired a new stake in Loxo Oncology in the 4th quarter valued at $118,000. Therefore 82% are positive. (NASDAQ:GILD) rating on Wednesday, February 3. This indicator compares the closing price of a stock in relation to the highs and lows over a certain time period. (NASDAQ:GILD) rating on Wednesday, February 7. On Thursday, November 2 the stock of Loxo Oncology, Inc. (NASDAQ:LOXO) on Tuesday, August 4 with "Buy" rating. Twelve investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. JMP Securities downgraded the stock to "Market Perform" rating in Tuesday, August 29 report.
LOXO has been the topic of a number of recent analyst reports. (NASDAQ:LOXO) earned "Buy" rating by Stifel Nicolaus on Wednesday, March 16. Jefferies has "Buy" rating and $95 target.
Weiss Asset Management Lp, which manages about $1.80 billion and $1.15 billion US Long portfolio, decreased its stake in Ani Pharmaceuticals Inc (NASDAQ:ANIP) by 143,450 shares to 11,639 shares, valued at $750,000 in 2017Q4, according to the filing. NY raised its stake in Loxo Oncology by 51.5% in the second quarter.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.